GlassScriptPhysician profile
Mitzi B Rubin
NPI 1154403582
$102,820.93
in general payments reported to CMS, 2019-2025
26 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,098 · 2020: $1,062 · 2021: $2,329 · 2022: $3,254 · 2023: $29K · 2024: $16K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $14K · Travel and Lodging: $9,963 · Food and Beverage: $4,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,450.00 |
| Consulting Fee | $13,930.00 |
| Travel and Lodging | $9,962.87 |
| Food and Beverage | $4,735.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $83,300.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,003.02 | 2025 | |
| Eli Lilly and Company | $1,950.00 | 2021-2022 | |
| Novo Nordisk INC | $1,766.06 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,297.29 | 2020-2021 | |
| Abbvie INC. | $268.78 | 2019-2024 | Synthroid, Vraylar |
| Currax Pharmaceuticals LLC | $185.78 | 2020-2025 | Contrave |
| Astrazeneca Pharmaceuticals LP | $180.29 | 2019-2020 | |
| Amgen INC. | $155.29 | 2019-2022 | |
| Allergan, INC. | $110.81 | 2020 | |
| Astellas Pharma US INC | $101.57 | 2019-2021 | |
| Dexcom, INC. | $89.03 | 2022-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $77.58 | 2024 | Inspire |
| Vivus LLC | $59.45 | 2023-2024 | Qsymia |
| Kvk-Tech, INC. | $42.40 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.46 | 2020-2021 | |
| Echosens North America, INC. | $27.50 | 2024 | Fibroscan |
| Jazz Pharmaceuticals INC. | $25.99 | 2022 | |
| Merck Sharp & Dohme LLC | $24.58 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $24.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.37 | 2023 | |
| Abbott Laboratories | $22.05 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.25 | 2019 | |
| Amarin Pharma, INC. | $14.19 | 2019 | |
| Pfizer INC. | $13.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitzi Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.